CYP2D6 and breast carcinoma: The role of TAM pharmacogenetics in breast cancer treatment outcomes has been extensively studied in Caucasian populations [16] The majority of the studies found that patients with the poor CYP2D6 metabolizer status (PM) responded poorly to TAM.